

Paul G Richardson

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5949616/publications.pdf](https://exaly.com/author-pdf/5949616/publications.pdf)

Version: 2024-02-01

851
papers

91,301
citations

209

143
h-index

365

277
g-index

961
all docs

961
docs citations

961
times ranked

43478
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	10.2	3,566
2	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	28.1	2,496
3	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. <i>New England Journal of Medicine</i> , 2003, 348, 2609-2617.	30.7	2,477
4	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2005, 352, 2487-2498.	30.7	2,373
5	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	10.2	2,003
6	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	30.7	1,801
7	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	5.3	1,613
8	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	30.7	1,245
9	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	30.7	1,166
10	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	30.7	1,044
11	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	30.7	972
12	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	30.7	968
13	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	1.4	877
14	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	16.9	868
15	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	1.4	867
16	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , 2000, 96, 2943-2950.	1.4	846
17	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , 2007, 7, 585-598.	27.8	833
18	NF- κ B as a Therapeutic Target in Multiple Myeloma. <i>Journal of Biological Chemistry</i> , 2002, 277, 16639-16647.	3.5	830

#	ARTICLE	IF	CITATIONS
19	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 116, 679-686.	1.4	799
20	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002, 100, 3063-3067.	1.4	763
21	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	13.2	763
22	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1551-1560.	12.2	746
23	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14374-14379.	7.6	694
24	The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. <i>Blood</i> , 2003, 101, 2377-2380.	1.4	679
25	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , 2005, 8, 407-419.	16.9	677
26	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.5	677
27	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , 2002, 99, 4525-4530.	1.4	641
28	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	609
29	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	5.3	591
30	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020, 21, 207-221.	10.2	590
31	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8567-8572.	7.6	574
32	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	5.3	559
33	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , 2003, 101, 1530-1534.	1.4	539
34	Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 157-168.	2.1	534
35	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 630-639.	5.3	531
36	A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. <i>Cancer Cell</i> , 2012, 22, 345-358.	16.9	508

#	ARTICLE	IF	CITATIONS
37	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	30.7	501
38	Workplace Violence against Health Care Workers in the United States. <i>New England Journal of Medicine</i> , 2016, 374, 1661-1669.	30.7	497
39	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006, 108, 3458-3464.	1.4	495
40	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	1.4	486
41	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	1.4	485
42	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	12.2	471
43	Activation of NF- κ B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , 2002, 21, 5673-5683.	5.9	458
44	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008, 112, 1329-1337.	1.4	447
45	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	1.4	446
46	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	30.7	434
47	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , 2017, 18, e206-e217.	10.2	412
48	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	5.3	409
49	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	1.4	405
50	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001, 98, 428-435.	1.4	401
51	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	1.4	401
52	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , 2007, 109, 3177-3188.	1.4	387
53	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014, 123, 3128-3138.	1.4	379
54	The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. <i>Oncogene</i> , 2001, 20, 4519-4527.	5.9	377

#	ARTICLE	IF	CITATIONS
55	Biologic sequelae of nuclear factor- κ B blockade in multiple myeloma: therapeutic applications. <i>Blood</i> , 2002, 99, 4079-4086.	1.4	370
56	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	5.3	364
57	TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. <i>Blood</i> , 2001, 98, 795-804.	1.4	361
58	Blockade of XBP1 splicing by inhibition of IRE1 α is a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012, 119, 5772-5781.	1.4	358
59	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	1.4	355
60	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , 2013, 121, 2975-2987.	1.4	348
61	CD38 antibodies in multiple myeloma: back to the future. <i>Blood</i> , 2018, 131, 13-29.	1.4	344
62	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	5.3	342
63	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	1.4	337
64	Bortezomib induces canonical nuclear factor- κ B activation in multiple myeloma cells. <i>Blood</i> , 2009, 114, 1046-1052.	1.4	333
65	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , 2002, 100, 4337-4343.	1.4	330
66	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 33-47.	12.5	319
67	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	5.3	315
68	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	1.4	312
69	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	1.4	309
70	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005, 128, 192-203.	2.8	308
71	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003, 102, 1578-1582.	1.4	303
72	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <i>Blood</i> , 2003, 101, 4055-4062.	1.4	296

#	ARTICLE	IF	CITATIONS
73	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , 2010, 16, 483-489.	30.5	291
74	<i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5311-5321.	7.3	291
75	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	2.8	290
76	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	1.4	285
77	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , 2013, 122, 2331-2337.	1.4	284
78	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , 2005, 107, 1092-1100.	1.4	279
79	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4607-4618.	7.3	279
80	Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. <i>Cancer Control</i> , 2003, 10, 361-369.	1.9	276
81	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004, 103, 1787-1790.	1.4	270
82	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.2	270
83	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	1.4	269
84	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , 2014, 123, 706-716.	1.4	262
85	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.2	258
86	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	30.5	258
87	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016, 127, 3225-3236.	1.4	258
88	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	5.3	257
89	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455.	5.3	252
90	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. <i>Blood</i> , 2010, 115, 5202-5213.	1.4	251

#	ARTICLE	IF	CITATIONS
91	Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2034-2042.	3.7	251
92	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	16.9	250
93	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 561-584.	6.3	249
94	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4784-4790.	5.3	248
95	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3518-3525.	5.3	245
96	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , 2007, 109, 2604-2606.	1.4	242
97	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	10.2	236
98	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1005-1017.	2.1	227
99	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.	7.3	224
100	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. <i>Blood</i> , 2003, 102, 2615-2622.	1.4	221
101	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196.	2.1	221
102	Bortezomib in recurrent and/or refractory multiple myeloma. <i>Cancer</i> , 2005, 103, 1195-1200.	4.1	219
103	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	30.7	219
104	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015, 55, 1545-1554.	1.9	210
105	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	7.3	208
106	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	12.2	207
107	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010, 116, 3227-3237.	1.4	203
108	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011, 117, 393-402.	1.4	201

#	ARTICLE	IF	CITATIONS
109	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1641-1653.	10.2	200
110	Latest advances and current challenges in the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 135-143.	27.9	195
111	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008, 111, 1654-1664.	1.4	194
112	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014, 124, 1038-1046.	1.4	192
113	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. <i>European Journal of Cancer</i> , 2006, 42, 1564-1573.	3.0	190
114	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 4906-4915.	1.4	190
115	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 502-507.	1.4	185
116	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1960-1965.	5.3	185
117	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.4	184
118	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 131, 71-73.	2.8	180
119	PI3K/p110 β is a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2010, 116, 1460-1468.	1.4	180
120	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	1.4	180
121	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	1.4	178
122	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 42-54.	27.9	178
123	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	1.4	174
124	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 1317-1330.	10.2	174
125	Colorectal Cancer on the Decline – Why Screening Can't Explain It All. <i>New England Journal of Medicine</i> , 2016, 374, 1605-1607.	30.7	172
126	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002, 21, 1346-1358.	5.9	170

#	ARTICLE	IF	CITATIONS
127	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , 2005, 106, 1794-1800.	1.4	170
128	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	2.4	168
129	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1569-1578.	10.2	167
130	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , 2003, 22, 8386-8393.	5.9	164
131	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.2	159
132	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5713-5719.	5.3	156
133	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	5.3	155
134	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013, 121, 1961-1967.	1.4	155
135	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	1.4	153
136	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	5.3	151
137	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.1	150
138	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 2764-2767.	1.4	146
139	New Drugs for Myeloma. <i>Oncologist</i> , 2007, 12, 664-689.	4.1	145
140	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2009, 114, 772-778.	1.4	145
141	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , 2011, 117, 4409-4419.	1.4	143
142	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b/2 dose-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e516-e527.	4.5	141
143	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e431-e442.	4.5	138
144	Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2555.	7.1	135

#	ARTICLE	IF	CITATIONS
145	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma. <i>Cancer</i> , 2006, 106, 1316-1319.	4.1	134
146	Kidney Disease and Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2007-2017.	4.6	133
147	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	2.4	130
148	Thalidomide: Emerging Role in Cancer Medicine. <i>Annual Review of Medicine</i> , 2002, 53, 629-657.	12.5	129
149	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. <i>Current Opinion in Hematology</i> , 2003, 10, 451-462.	2.6	129
150	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , 2004, 23, 8766-8776.	5.9	129
151	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , 2011, 86, 23-31.	2.3	128
152	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	5.3	125
153	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.	4.5	125
154	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ^EELOQUENT follow-up and ^{post-hoc} analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.8	124
155	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , 2004, 103, 3158-3166.	1.4	123
156	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	5.3	123
157	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.	1.4	122
158	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT trial. <i>Cancer</i> , 2018, 124, 4032-4043.	4.1	122
159	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 222-230.	2.8	122
160	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity ^{in vitro} and ^{in vivo}. <i>British Journal of Haematology</i> , 2010, 149, 537-549.	2.8	121
161	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	1.4	121
162	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. <i>Mayo Clinic Proceedings</i> , 2004, 79, 875-882.	2.9	120

#	ARTICLE	IF	CITATIONS
163	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. <i>British Journal of Haematology</i> , 2011, 152, 367-379.	2.8	120
164	Treatment Options for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1264-1277.	7.3	118
165	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4243-4249.	5.3	118
166	How I treat plasma cell leukemia. <i>Blood</i> , 2012, 120, 2376-2389.	1.4	118
167	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13162-13167.	7.6	118
168	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.	2.8	116
169	Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. <i>Blood</i> , 2003, 101, 703-705.	1.4	114
170	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	13.2	113
171	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. <i>Blood</i> , 2002, 100, 2187-2194.	1.4	110
172	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1007-1034.	1.9	110
173	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007, 110, 1656-1663.	1.4	109
174	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	5.3	109
175	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 115, 834-845.	1.4	106
176	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.	1.4	103
177	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 138, 783-791.	2.8	102
178	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	1.4	102
179	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , 2011, 153, 729-740.	2.8	102
180	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results.. <i>Blood</i> , 2005, 106, 1565-1565.	1.4	102

#	ARTICLE	IF	CITATIONS
181	Final results from a defibrotide treatmentâ€‹IND› study for patients with hepatic venoâ€‹occlusive disease/sinusoidal obstruction syndrome. British Journal of Haematology, 2018, 181, 816-827.	2.8	101
182	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood, 2015, 126, 391-391.	1.4	100
183	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer, 2005, 104, 2141-2148.	4.1	99
184	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discovery, 2015, 5, 972-987.	14.3	99
185	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 2016, 128, 1821-1828.	1.4	99
186	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	98
187	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood, 2017, 130, 2610-2618.	1.4	95
188	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 2008, 143, 46-53.	2.8	94
189	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood, 2016, 127, 1138-1150.	1.4	94
190	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology, 2008, 143, 222-229.	2.8	93
191	Proteasome Inhibition in the Treatment of Cancer. Cell Cycle, 2005, 4, 289-295.	2.8	92
192	â€‹TAK› (formerly â€‹MLN›0128), an investigational oral dual â€‹TORC›1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, nonâ€‹Hodgkin lymphoma, or Waldenstrâ€‹m's macroglobulinemia. American Journal of Hematology, 2016, 91, 400-405.	4.3	92
193	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 623-633.	3.4	91
194	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncology, The, 2011, 12, 263-272.	10.2	90
195	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematology,the, 2021, 8, e45-e54.	4.5	90
196	Prediction of VenO-occlusive Disease Using Biomarkers of Endothelial Injury. Biology of Blood and Marrow Transplantation, 2010, 16, 1180-1185.	2.1	89
197	New Proteasome Inhibitors in Myeloma. Current Hematologic Malignancy Reports, 2012, 7, 258-266.	2.4	89
198	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. British Journal of Haematology, 2005, 132, 051220022257014.	2.8	88

#	ARTICLE	IF	CITATIONS
199	<i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 3019-3031.	7.3	88
200	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Blood</i> , 2004, 103, 3474-3479.	1.4	87
201	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	13.2	87
202	Promising therapies in multiple myeloma. <i>Blood</i> , 2015, 126, 300-310.	1.4	86
203	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	6.4	86
204	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 537-540.	2.8	85
205	THE PATHOLOGY, DIAGNOSIS, AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE: CURRENT STATUS AND NOVEL APPROACHES. <i>British Journal of Haematology</i> , 1999, 107, 485-493.	2.8	83
206	Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 950-968.	2.6	83
207	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , 2019, 134, 123-133.	1.4	83
208	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011, 118, 535-543.	1.4	82
209	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	5.8	82
210	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	4.5	82
211	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies. <i>JAMA Oncology</i> , 2017, 3, 980.	7.4	81
212	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020, 136, 39-39.	1.4	81
213	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 8-17.e16.	0.4	80
214	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.8	80
215	Clinical update: proteasome inhibitors in hematologic malignancies. <i>Cancer Treatment Reviews</i> , 2003, 29, 33-39.	8.1	79
216	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , 2004, 104, 2458-2466.	1.4	79

#	ARTICLE	IF	CITATIONS
217	Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1053-1072.	2.5	79
218	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology, 2009, 146, 164-170.	2.8	79
219	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. Journal of Clinical Oncology, 2011, 29, 1916-1923.	5.3	79
220	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biology of Blood and Marrow Transplantation, 2016, 22, 1874-1882.	2.1	79
221	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 178, 112-118.	2.8	77
222	Dual Inhibition of Canonical and Noncanonical NF- κ B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research, 2012, 18, 4669-4681.	7.3	76
223	Intracellular NAD ⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood, 2013, 122, 1243-1255.	1.4	75
224	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	2.8	74
225	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 344-353.	7.3	74
226	Drug safety evaluation of defibrotide. Expert Opinion on Drug Safety, 2013, 12, 123-136.	2.5	73
227	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood, 2015, 126, 921-922.	1.4	73
228	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	2.5	73
229	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. British Journal of Haematology, 2010, 150, 438-445.	2.8	72
230	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica, 2011, 96, 1170-1179.	3.5	72
231	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 416-427.	10.2	72
232	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology, 2010, 150, 428-437.	2.8	71
233	Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood, 2012, 120, 3958-3967.	1.4	71
234	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. Cell Reports, 2021, 34, 108532.	6.4	71

#	ARTICLE	IF	CITATIONS
235	Biologic sequelae of $\hat{\text{I}}^{\text{B}}$ kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009, 113, 5228-5236.	1.4	70
236	Sequence analysis of $\hat{\text{I}}^2$ -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. <i>Blood</i> , 2012, 120, 4513-4516.	1.4	70
237	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	1.4	70
238	Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6345-6350.	5.3	69
239	Monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2011, 154, 745-754.	2.8	69
240	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, e183267.	7.4	69
241	Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3212-3214.	5.3	68
242	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomideâ€“bortezomib combinations. <i>British Journal of Haematology</i> , 2015, 169, 843-850.	2.8	68
243	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016, 127, 2693-2700.	1.4	67
244	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017, 8, 66641-66655.	1.8	67
245	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.9	66
246	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.1	66
247	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1â€“2 study. <i>Lancet Haematology</i> , 2020, 7, e395-e407.	4.5	66
248	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. <i>Clinical Cancer Research</i> , 2009, 15, 7153-7160.	7.3	65
249	Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design. <i>Future Oncology</i> , 2018, 14, 1035-1047.	2.4	65
250	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 1448-1453.	2.7	65
251	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 797-816.	1.9	64
252	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.	7.3	64

#	ARTICLE	IF	CITATIONS
253	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	1.4	64
254	Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide. <i>Seminars in Hematology</i> , 2005, 42, S9-S15.	4.1	63
255	Genetic variation associated with bortezomib-induced peripheral neuropathy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 121-129.	1.5	63
256	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NCT00524107): final study results. <i>British Journal of Haematology</i> , 2018, 180, 41-51.	2.8	63
257	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1357-1368.	2.4	62
258	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019, 33, 426-438.	7.5	62
259	Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2001, 106, 57-68.	1.4	61
260	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	4.5	61
261	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	61
262	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , 2012, 120, 73-73.	1.4	61
263	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.	4.3	60
264	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , 2004, 36, 304-314.	3.9	59
265	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005, 105, 4470-4476.	1.4	59
266	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 149-162.	5.4	59
267	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	5.3	59
268	Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. <i>Blood</i> , 2008, 112, 4343-4352.	1.4	58
269	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). <i>Bone Marrow Transplantation</i> , 2019, 54, 1951-1962.	2.5	58
270	Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. <i>Haematologica</i> , 2011, 96, 1662-1669.	3.5	57

#	ARTICLE	IF	CITATIONS
271	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	1.4	57
272	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	17.8	57
273	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.	2.8	56
274	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. <i>British Journal of Haematology</i> , 2012, 158, 472-480.	2.8	55
275	The use of defibrotide in blood and marrow transplantation. <i>Blood Advances</i> , 2018, 2, 1495-1509.	5.5	55
276	Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. <i>Seminars in Hematology</i> , 2009, 46, 166-175.	4.1	54
277	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	1.4	54
278	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	2.8	54
279	The Treatment of Relapsed and Refractory Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 317-323.	2.6	53
280	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1306-1312.	2.1	53
281	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1165-1173.	2.5	52
282	Marizomib for central nervous system multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 221-225.	2.8	52
283	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010, 116, 1397-1404.	1.4	51
284	A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , 2016, 174, 397-409.	2.8	51
285	Selinexor for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 399-408.	1.9	51
286	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 568-578.	5.3	51
287	Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 1999, 17, 1175-1175.	5.3	50
288	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 942-951.	3.7	50

#	ARTICLE	IF	CITATIONS
289	Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes. <i>Oral Oncology</i> , 2013, 49, 977-983.	1.9	50
290	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	3.5	50
291	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , 2016, 7, 77326-77341.	1.8	49
292	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.1	49
293	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	5.3	49
294	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 142-154.	10.2	49
295	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.5	49
296	Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Venous Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action. <i>Oligonucleotides</i> , 2006, 16, 105-114.	2.7	48
297	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 99-127.	2.5	48
298	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 829-837.	1.1	48
299	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	2.8	48
300	Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 233-235.	1.8	47
301	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.8	47
302	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	1.9	47
303	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2003, 121, 592-596.	2.8	46
304	Novel biological therapies for the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 619-634.	1.9	46
305	Daratumumab granted breakthrough drug status. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 445-452.	4.2	46
306	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2022, 57, 95-105.	2.2	46

#	ARTICLE	IF	CITATIONS
307	Novel biologically based therapies for Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 309-312.	2.4	45
308	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2012, 5, 291-302.	2.2	45
309	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016, 174, 711-720.	2.8	45
310	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.3	45
311	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018, 32, 1838-1841.	7.5	45
312	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	7.5	45
313	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 635-644.	2.1	44
314	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	3.5	44
315	Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1590-1599.	5.3	44
316	A review of the proteasome inhibitor bortezomib in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1321-1331.	1.9	43
317	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- ² inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	5.9	43
318	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	4.3	43
319	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 253-265.	2.7	42
320	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	4.3	42
321	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 106.	6.4	42
322	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 804-804.	1.4	42
323	Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 370-376.	0.4	41
324	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. <i>British Journal of Haematology</i> , 2015, 171, 798-812.	2.8	41

#	ARTICLE	IF	CITATIONS
325	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	4.5	41
326	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1341-1347.	2.3	40
327	Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 373-388.	2.8	40
328	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	3.5	40
329	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , 2015, 21, 2660-2662.	7.3	40
330	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.1	40
331	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	7.5	40
332	Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.. <i>Blood</i> , 2006, 108, 405-405.	1.4	40
333	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-744.	1.9	39
334	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017, 129, 1308-1319.	1.4	39
335	Current use of monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 447-459.	2.8	39
336	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	6.4	39
337	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	2.9	39
338	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2022, 36, 138-154.	7.5	39
339	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	1.4	38
340	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	1.4	38
341	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	2.6	38
342	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. <i>Cancer</i> , 1998, 83, 409-414.	4.1	37

#	ARTICLE	IF	CITATIONS
343	Novel Therapies in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 947-960.	5.4	37
344	The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagulation and Fibrinolysis, 2009, 20, 627-634.	1.1	37
345	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. British Journal of Haematology, 2014, 166, 401-409.	2.8	37
346	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood, 2019, 134, 691-691.	1.4	37
347	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. Blood, 2004, 104, 336-336.	1.4	37
348	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. Blood, 2015, 126, 23-23.	1.4	37
349	Pathological crystallization of human immunoglobulins. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13359-13361.	7.6	36
350	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Therapeutics and Clinical Risk Management, 2008, Volume 4, 129-136.	2.1	35
351	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-4-S-12.	5.4	35
352	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 2020, 13, 421-433.	2.2	35
353	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. American Journal of Hematology, 2007, 82, 831-833.	4.3	34
354	The evolution and impact of therapy in multiple myeloma. Medical Oncology, 2010, 27, 1-6.	2.7	34
355	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. Clinical Cancer Research, 2014, 20, 3955-3961.	7.3	34
356	The power of proteasome inhibition in multiple myeloma. Expert Review of Proteomics, 2018, 15, 1033-1052.	3.2	34
357	A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer Journal, 2021, 11, 23.	6.4	34
358	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. Blood, 2008, 112, 92-92.	1.4	34
359	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. Blood, 2017, 130, 741-741.	1.4	34
360	Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncology, 2005, 1, 161-167.	2.4	33

#	ARTICLE	IF	CITATIONS
361	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , 2011, 11, 1391-1402.	2.7	33
362	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, 100-106.	3.5	33
363	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 433-446.	2.8	33
364	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , 2006, 18, 598-608.	2.5	32
365	Realgar nanoparticles versus ATO arsenic compounds induce <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 756-771.	2.8	32
366	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018, 180, 821-830.	2.8	32
367	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 478-486.	7.3	32
368	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	2.8	32
369	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	1.4	32
370	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 694-702.	1.4	31
371	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	9.7	31
372	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	2.8	31
373	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.8	31
374	Compartment-Specific Bioluminescence Imaging (CS-BLI) High-Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics. <i>Blood</i> , 2008, 112, 219-219.	1.4	31
375	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , 2012, 5, 51-68.	2.2	30
376	Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S36-S44.	4.6	30
377	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	4.2	30
378	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). <i>Blood</i> , 2015, 126, 507-507.	1.4	30

#	ARTICLE	IF	CITATIONS
379	Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. <i>Blood</i> , 2012, 119, e131-e138.	1.4	29
380	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012, 4, 253.	2.1	29
381	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016, 22, 4206-4214.	7.3	29
382	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.4	29
383	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	2.8	28
384	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1817-1825.	2.1	28
385	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 942-945.	2.5	28
386	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , 2019, 33, 2208-2226.	7.5	28
387	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	6.3	28
388	Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trial. <i>Blood</i> , 2005, 106, 2547-2547.	1.4	28
389	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	1.4	28
390	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor " Microenvironment Interactions. <i>Blood</i> , 2010, 116, 1574-1574.	1.4	28
391	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	7.3	27
392	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 113-124.	3.2	27
393	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019, 10, 486-489.	1.1	27
394	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	3.5	27
395	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021, 23, 1199-1211.	10.1	27
396	<i>In vitro</i> anti-myeloma activity of the Aurora kinase inhibitor VE-821. <i>British Journal of Haematology</i> , 2009, 147, 672-676.	2.8	26

#	ARTICLE	IF	CITATIONS
397	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2308-2315.	1.4	26
398	Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.	2.8	26
399	The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple Myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	2.4	26
400	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 885-898.	3.1	26
401	Defibrotide for the Treatment of Hepatic Venous Obstruction Syndrome with Multiorgan Failure. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 75-93.	1.3	26
402	Phase I Trial of CCI-779 (Temsirrolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3696-3696.	1.4	26
403	SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. <i>Blood</i> , 2014, 124, 3441-3441.	1.4	26
404	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	2.6	25
405	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 271-275.	2.8	25
406	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded access program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27269.	1.6	25
407	Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	2.4	25
408	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 406-406.	1.4	25
409	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	1.4	25
410	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2023, 58, 749-754.	2.5	25
411	Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 127-131.	2.8	24
412	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	3.2	24
413	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	2.2	24
414	Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review. <i>Expert Review of Hematology</i> , 2017, 10, 169-174.	2.2	24

#	ARTICLE	IF	CITATIONS
415	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	3.7	24
416	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1395-1404.	3.2	24
417	The role of high-dose melphalan with autologous stem cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	2.8	24
418	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 351-357.	0.4	24
419	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. <i>Blood Cancer Journal</i> , 2022, 12, .	6.4	24
420	Prevention and Treatment of Hepatic Venocclusive Disease after High-Dose Cytoreductive Therapy. <i>Leukemia and Lymphoma</i> , 1998, 31, 267-277.	1.4	23
421	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011, 4, 51-60.	2.2	23
422	Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. <i>British Journal of Haematology</i> , 2011, 152, 420-432.	2.8	23
423	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. <i>Journal of Clinical Oncology</i> , 2014, 32, 2125-2132.	5.3	23
424	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 793-798.	2.1	23
425	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	2.3	23
426	Incidence of Anicteric Venocclusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1342-1349.	2.1	23
427	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016, 128, 1148-1148.	1.4	23
428	Management of Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1209-1216.	5.4	22
429	Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. <i>Current Medical Research and Opinion</i> , 2017, 33, 973-980.	2.0	22
430	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2011, 86, 573-578.	4.3	21
431	Combination of a Selective HSP90 α / β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015, 10, e0143847.	2.4	21
432	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 756-763.	2.8	21

#	ARTICLE	IF	CITATIONS
433	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled <sc>PANORAMA</sc> trial. British Journal of Haematology, 2018, 181, 628-636.	2.8	21
434	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. American Journal of Hematology, 2021, 96, E5-E8.	4.3	21
435	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. Blood, 2015, 126, 395-395.	1.4	21
436	Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplantation and Cellular Therapy, 2023, 29, 174.e1-174.e10.	2.6	21
437	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. British Journal of Haematology, 2013, 160, 351-358.	2.8	20
438	Serrated Au/Pd Core/Shell Nanowires with Jagged Edges for Boosting Liquid Fuel Electrooxidation. ChemSusChem, 2017, 10, 2375-2379.	7.4	20
439	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia Research, 2021, 104, 106576.	1.1	20
440	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood, 2020, 136, 45-46.	1.4	20
441	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) Tj ETQq1 1.0.784314orgBT / O	1.4	20
442	Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Advances, 2022, 6, 181-188.	5.5	20
443	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.	1.4	20
444	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. British Journal of Haematology, 2011, 154, 755-762.	2.8	19
445	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5688-5695.	7.3	19
446	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology, 2017, 12, 643-654.	3.7	19
447	New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. Journal of Blood Medicine, 2017, Volume 8, 107-121.	1.8	19
448	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 529-539.	2.1	19
449	Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. Blood, 2009, 114, 127-127.	1.4	19
450	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. Blood, 2013, 122, 535-535.	1.4	19

#	ARTICLE	IF	CITATIONS
451	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 759-759.	1.4	19
452	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015, 126, 375-375.	1.4	19
453	Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2123-2123.	1.4	19
454	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , 2021, 138, 2731-2731.	1.4	19
455	Novel therapies in myeloma. <i>Current Opinion in Hematology</i> , 2007, 14, 609-615.	2.6	18
456	Panobinostat for the treatment of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, 1178-1179.	10.2	18
457	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <sc>PANORAMA</sc> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	2.8	18
458	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	2.8	18
459	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.3	18
460	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	7.3	18
461	A phase I<sc>II</sc> study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance <sc>A061202</sc>). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.3	18
462	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , 2007, 110, 1165-1165.	1.4	18
463	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	1.4	18
464	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	1.4	18
465	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , 2015, 126, 3040-3040.	1.4	18
466	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2016, 128, 976-976.	1.4	18
467	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010, 4, 215.	3.8	18
468	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	4.2	17

#	ARTICLE	IF	CITATIONS
469	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020, 9, 378.	4.3	17
470	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.3	17
471	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	1.4	17
472	A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2005, 106, 365-365.	1.4	17
473	Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity. <i>Blood</i> , 2007, 110, 1164-1164.	1.4	17
474	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. <i>Blood</i> , 2010, 116, 1951-1951.	1.4	17
475	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011, 118, 476-476.	1.4	17
476	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	1.4	17
477	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , 2014, 124, 3453-3453.	1.4	17
478	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.4	17
479	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. <i>Cancer</i> , 2022, 128, 1996-2004.	4.1	17
480	Novel Targeted Agents in the Treatment of Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 903-925.	1.9	16
481	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. <i>British Journal of Haematology</i> , 2015, 170, 66-79.	2.8	16
482	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	2.8	16
483	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	2.6	16
484	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008, 112, 93-93.	1.4	16
485	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014, 124, 3081-3081.	1.4	16
486	Recent Advances in the Treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 381-393.	1.7	15

#	ARTICLE	IF	CITATIONS
487	Use of defibrotide in the treatment and prevention of veno-occlusive disease. <i>Expert Review of Hematology</i> , 2009, 2, 365-376.	2.2	15
488	Bortezomib and dexamethasone induction for multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 8-10.	27.9	15
489	Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 75-82.	2.8	15
490	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 465-476.	2.5	14
491	Stabilizing Single Ni Adatoms on a Two-Dimensional Porous Titania Overlayer at the SrTiO ₃ (110) Surface. <i>Journal of Physical Chemistry C</i> , 2014, 118, 19904-19909.	3.3	14
492	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010, 116, 621-621.	1.4	14
493	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3483-3483.	1.4	14
494	Characterization of haematological parameters with bortezomib versus melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	2.8	13
495	Multiple Myeloma in Pregnancy: A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e39-e45.	0.4	13
496	Competitive Energy and Electron Transfer in Functionalized Free-Base Porphyrin-Zinc Porphyrin Dimer Axially Coordinated to C ₆₀ : Synthesis, Supramolecular Formation and Excited State Processes. <i>Chemistry - A European Journal</i> , 2017, 23, 12805-12814.	3.9	13
497	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	7.5	13
498	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.8	13
499	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.5	13
500	ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. <i>Science Advances</i> , 2021, 7, .	10.9	13
501	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	2.5	13
502	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	1.4	13
503	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	1.4	13
504	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control. <i>Blood</i> , 2009, 114, 654-654.	1.4	13

#	ARTICLE	IF	CITATIONS
505	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1078-1087.	7.5	13
506	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> , 2022, 199, 190-204.	2.8	13
507	Plasma Cell Problems. <i>Journal of Clinical Oncology</i> , 2005, 23, 3138-3140.	5.3	12
508	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 551-566.	2.5	12
509	Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. <i>Blood</i> , 2013, 121, 858-858.	1.4	12
510	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1291-1301.	3.2	12
511	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , 2017, 10, 933-939.	2.2	12
512	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (<scp>GEN</scp>503): final results of an openâ€label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	2.8	12
513	Clinical benefit of ixazomib plus lenalidomideâ€dexamethasone in myeloma patients with nonâ€canonical NFâ€B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	2.3	12
514	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: longâ€term survival followâ€up from the Phase II study Oâ€12â€M1. <i>British Journal of Haematology</i> , 2021, 193, 1105-1109.	2.8	12
515	Phase I open-label study of panobinostat, lenalidomide, bortezomibâ€+â€dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	6.4	12
516	Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	2.4	12
517	OP-106 Horizon â€” Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018, 132, 600-600.	1.4	12
518	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	1.4	12
519	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2010, 116, 3013-3013.	1.4	12
520	MM-005: A Phase I Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	1.4	12
521	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , 2013, 122, 1976-1976.	1.4	12
522	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	1.4	12

#	ARTICLE	IF	CITATIONS
523	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	1.4	12
524	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007, 110, 3507-3507.	1.4	12
525	Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3986-3986.	1.4	12
526	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	1.4	12
527	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 155-163.	2.5	11
528	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	2.3	11
529	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	1.4	11
530	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.4	11
531	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <sc>ICARIA&MM</sc> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	4.3	11
532	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020, 136, 4-5.	1.4	11
533	Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 3691-3691.	1.4	11
534	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009, 114, 1852-1852.	1.4	11
535	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011, 118, 1881-1881.	1.4	11
536	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	1.4	11
537	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	1.4	11
538	Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the <sc>GRIFFIN</sc> study. <i>British Journal of Haematology</i> , 2022, 199, 355-365.	2.8	11
539	An update of novel therapeutic approaches for multiple myeloma. <i>Current Treatment Options in Oncology</i> , 2004, 5, 227-238.	3.2	10
540	Case 38-2004. <i>New England Journal of Medicine</i> , 2004, 351, 2637-2645.	30.7	10

#	ARTICLE	IF	CITATIONS
541	Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone. <i>Journal of Clinical Oncology</i> , 2012, 30, e175-e179.	5.3	10
542	The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. <i>European Journal of Haematology</i> , 2012, 88, 446-449.	2.3	10
543	Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 82-88.	2.8	10
544	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	1.9	10
545	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	2.5	10
546	Randomized, placebo-controlled, phase 3 study of perfosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	10
547	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , 2019, 134, 1883-1883.	1.4	10
548	Phase I/II Report from a Multicenter Trial of Perfosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. <i>Blood</i> , 2007, 110, 1170-1170.	1.4	10
549	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1179-1179.	1.4	10
550	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	1.4	10
551	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015, 126, 1827-1827.	1.4	10
552	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , 2007, 110, 1519-1519.	1.4	10
553	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2008, 112, 2648-2648.	1.4	10
554	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , 2009, Volume 1, 107-117.	2.1	9
555	Clinical Translation in Multiple Myeloma: From Bench to Bedside. <i>Seminars in Oncology</i> , 2013, 40, 549-553.	2.4	9
556	Contrasting genomic and phenotypic outcomes of hybridization between pairs of mimetic butterfly taxa across a suture zone. <i>Molecular Ecology</i> , 2020, 29, 1328-1343.	3.6	9
557	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic venoocclusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 583-587.	2.8	9
558	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 48-55.	1.0	9

#	ARTICLE	IF	CITATIONS
559	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	2.3	9
560	Proteasome inhibitors as therapeutics. <i>Essays in Biochemistry</i> , 2005, 41, 205-218.	4.7	9
561	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010, 116, 3952-3952.	1.4	9
562	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 301-301.	1.4	9
563	Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. <i>Blood</i> , 2010, 116, 3023-3023.	1.4	9
564	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	4.3	9
565	Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. <i>Blood Cancer Journal</i> , 2023, 13, .	6.4	9
566	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , 2002, 76, 340-341.	1.6	8
567	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e353-e354.	0.4	8
568	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	1.9	8
569	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	2.3	8
570	RAPIDO protocol: a promising approach for high-risk locally advanced rectal cancers. <i>Lancet Oncology</i> , The, 2021, 22, 2-3.	10.2	8
571	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	3.4	8
572	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1857-1857.	1.4	8
573	Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 1503-1503.	1.4	8
574	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , 2005, 106, 247-247.	1.4	8
575	A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3582-3582.	1.4	8
576	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4217-4217.	1.4	8

#	ARTICLE	IF	CITATIONS
577	Defibrotide Therapy for SARS-CoV-2 ARDS. <i>Chest</i> , 2022, 162, 346-355.	0.9	8
578	Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 239-246.	2.4	7
579	Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 84-88.	1.8	7
580	Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2008, 100, 373-373.	6.6	7
581	Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. <i>Lancet Oncology</i> , The, 2010, 11, 1014-1016.	10.2	7
582	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*. <i>European Journal of Haematology</i> , 2012, 88, 1-7.	2.3	7
583	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 169-194.	0.0	7
584	Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the microenvironmental dialogue. <i>British Journal of Haematology</i> , 2017, 178, 949-953.	2.8	7
585	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e33.	0.4	7
586	Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.. <i>Blood</i> , 2004, 104, 286-286.	1.4	7
587	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008, 112, 832-832.	1.4	7
588	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009, 114, 132-132.	1.4	7
589	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4772-4772.	1.4	7
590	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4220-4220.	1.4	7
591	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.8	7
592	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. <i>Blood</i> , 2010, 116, 456-456.	1.4	7
593	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021, 138, 2852-2852.	1.4	7
594	Selinexor: Targeting a novel pathway in multiple myeloma. <i>EJHaem</i> , 2023, 4, 792-810.	1.0	7

#	ARTICLE	IF	CITATIONS
595	Toward a new therapeutic backbone in myeloma. <i>Blood</i> , 2007, 109, 2672-2673.	1.4	6
596	The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. <i>Expert Review of Hematology</i> , 2014, 7, 1-3.	2.2	6
597	The challenge of cross-trial comparisons using limited data. <i>Haematologica</i> , 2014, 99, e145-e146.	3.5	6
598	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.4	6
599	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. <i>Blood Cancer Journal</i> , 2020, 10, 29.	6.4	6
600	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	2.2	6
601	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	1.4	6
602	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3169-3169.	1.4	6
603	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. <i>Blood</i> , 2020, 136, 15-17.	1.4	6
604	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. <i>Blood</i> , 2004, 104, 2403-2403.	1.4	6
605	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. <i>Blood</i> , 2005, 106, 1571-1571.	1.4	6
606	Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3532-3532.	1.4	6
607	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3700-3700.	1.4	6
608	Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. <i>Blood</i> , 2009, 114, 2890-2890.	1.4	6
609	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010, 116, 986-986.	1.4	6
610	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 1852-1852.	1.4	6
611	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , 2016, 128, 3326-3326.	1.4	6
612	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6

#	ARTICLE	IF	CITATIONS
613	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 19-26.	2.4	6
614	Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 394-395.	2.3	5
615	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. <i>Mayo Clinic Proceedings</i> , 2010, 85, 197-199.	2.9	5
616	Evolving Strategies in the Initial Treatment of Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 592-601.	2.4	5
617	Usefulness of the EMA flow cytometric test in the diagnosis of hereditary spherocytosis post-transfusion. <i>British Journal of Haematology</i> , 2017, 178, 180-180.	2.8	5
618	ICARIA-MM study: efficacy analysis according to prior lines of treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e245-e246.	0.4	5
619	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.4	5
620	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 55.	6.4	5
621	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , 2005, 106, 109-109.	1.4	5
622	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. <i>Blood</i> , 2010, 116, 3481-3481.	1.4	5
623	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010, 116, 990-990.	1.4	5
624	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2933-2933.	1.4	5
625	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 479-479.	1.4	5
626	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes. <i>Blood</i> , 2012, 120, 4072-4072.	1.4	5
627	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013, 122, 4402-4402.	1.4	5
628	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). <i>Blood</i> , 2015, 126, 3055-3055.	1.4	5
629	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	6.4	5
630	Hemostatic Complications of Hematopoietic Stem Cell Transplantation: From Hemorrhage to Microangiopathies and VOD. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 50-53.	0.3	4

#	ARTICLE	IF	CITATIONS
631	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 698-704.	2.8	4
632	Improving the therapeutic index in myeloma. <i>Blood</i> , 2010, 116, 4733-4734.	1.4	4
633	Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 344-348.	2.1	4
634	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 337-347.	0.7	4
635	Pomalidomide in lenalidomideâ€refractory multiple myeloma: Far from futile. <i>British Journal of Haematology</i> , 2020, 188, 483-485.	2.8	4
636	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	2.3	4
637	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 88.e1-88.e6.	2.6	4
638	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq0 0 0 rgBT /Overlock 40 Tf 50 45		
639	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , 2020, 136, 7-8.	1.4	4
640	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2006, 108, 3485-3485.	1.4	4
641	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , 2010, 116, 3051-3051.	1.4	4
642	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT). <i>Blood</i> , 2012, 120, 4053-4053.	1.4	4
643	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1970-1970.	1.4	4
644	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 2120-2120.	1.4	4
645	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4256-4256.	1.4	4
646	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011, 118, 1838-1838.	1.4	4
647	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	1.4	4
648	Pomalidomideâ€bortezomibâ€dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. <i>Cancer Science</i> , 2020, 111, 2116-2122.	4.0	4

#	ARTICLE	IF	CITATIONS
649	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1613-1613.	1.4	4
650	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , 2020, 136, 2-4.	1.4	4
651	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	3.2	4
652	Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2403-2412.	1.4	4
653	Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer. <i>Bone Marrow Transplantation</i> , 2023, 58, 839-841.	2.5	4
654	Can thalidomide improve outcome in patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 590-591.	2.3	3
655	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. <i>Biologics: Targets and Therapy</i> , 2008, 2, 419.	3.6	3
656	Reply to C.A. Dasanu et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2294-2296.	5.3	3
657	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S110.	2.1	3
658	Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e283.	0.4	3
659	Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. <i>EJHaem</i> , 2021, 2, 680-681.	1.0	3
660	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. <i>Blood</i> , 2020, 136, 41-43.	1.4	3
661	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. <i>Blood</i> , 2004, 104, 2404-2404.	1.4	3
662	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , 2004, 104, 2405-2405.	1.4	3
663	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004, 104, 751-751.	1.4	3
664	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 3380-3380.	1.4	3
665	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3662-3662.	1.4	3
666	Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.. <i>Blood</i> , 2009, 114, 1871-1871.	1.4	3

#	ARTICLE	IF	CITATIONS
667	Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).. Blood, 2010, 116, 3482-3482.	1.4	3
668	Defibrotide (DF) In the Treatment of Severe Hepatic VenO-occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. Blood, 2010, 116, 906-906.	1.4	3
669	Defibrotide (DF) in the Treatment of Hepatic VenO-occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. Blood, 2011, 118, 487-487.	1.4	3
670	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). Blood, 2012, 120, 4039-4039.	1.4	3
671	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. Blood, 2015, 126, 3031-3031.	1.4	3
672	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 243-243.	1.4	3
673	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic VenO-occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. Blood, 2016, 128, 66-66.	1.4	3
674	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. Blood, 2004, 104, 3413-3413.	1.4	3
675	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. Blood, 2008, 112, 1716-1716.	1.4	3
676	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. Blood, 2009, 114, 2846-2846.	1.4	3
677	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. Blood, 2019, 134, 3487-3487.	1.4	3
678	Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?. Exploration of Targeted Anti-tumor Therapy, 0, , 617-626.	0.8	3
679	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2022, 97, 562-573.	4.3	3
680	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	2.7	3
681	A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opinion on Drug Safety, 2023, 22, 1049-1071.	2.5	3
682	Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer Journal, 2024, 14, .	6.4	3
683	Management Strategies for Relapsed Multiple Myeloma. American Journal of Cancer, 2006, 5, 393-409.	0.4	2
684	Emerging Therapies for Multiple Myeloma. American Journal of Cancer, 2006, 5, 141-153.	0.4	2

#	ARTICLE	IF	CITATIONS
685	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008, , .	0.1	2
686	THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010009.	1.1	2
687	Setting the standard for newly diagnosed multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 255-256.	27.9	2
688	Dual inhibition of oncogenic targets for B-cell malignancies. <i>Lancet Oncology</i> , The, 2016, 17, 547-549.	10.2	2
689	The Future of Myeloma Therapy: One Size Does Not Fit All. <i>Journal of Oncology Practice</i> , 2016, 12, 295-296.	3.1	2
690	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. <i>International Journal of Dermatology</i> , 2017, 56, 1058-1060.	1.0	2
691	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e352-e353.	0.4	2
692	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018, 132, 1967-1967.	1.4	2
693	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. <i>Blood</i> , 2019, 134, 1839-1839.	1.4	2
694	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
695	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , 2020, 136, 44-46.	1.4	2
696	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006, 108, 3468-3468.	1.4	2
697	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , 2007, 110, 1185-1185.	1.4	2
698	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.	1.4	2
699	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
700	A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.. <i>Blood</i> , 2008, 112, 1719-1719.	1.4	2
701	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1943-1943.	1.4	2
702	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	1.4	2

#	ARTICLE	IF	CITATIONS
703	Blockade of XBP1 Splicing by Inhibition of IRE1 \hat{t} Is a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011, 118, 133-133.	1.4	2
704	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma â€œ Preliminary Safety Data. <i>Blood</i> , 2011, 118, 1873-1873.	1.4	2
705	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011, 118, 3966-3966.	1.4	2
706	Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study. <i>Blood</i> , 2012, 120, 4052-4052.	1.4	2
707	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1869-1869.	1.4	2
708	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015, 126, 4246-4246.	1.4	2
709	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 169.	6.4	2
710	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , 2004, 104, 1498-1498.	1.4	2
711	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3396-3396.	1.4	2
712	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstroïm's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010, 116, 2988-2988.	1.4	2
713	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014, 124, 27-27.	1.4	2
714	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8012-8012.	5.3	2
715	Allogeneic Transplantation in Multiple Myeloma: A Potential Renaissance in the Era of Novel Therapies?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1078-1079.	2.1	1
716	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1491-1501.	0.7	1
717	Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S337.	0.4	1
718	Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S335-S336.	0.4	1
719	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation â€œ a case series. <i>British Journal of Haematology</i> , 2021, 193, e36-e38.	2.8	1
720	Multiple myeloma triplet therapies: baseline characteristics and control groups â€œ Authors' reply. <i>Lancet</i> , The, 2021, 397, 1621-1623.	12.2	1

#	ARTICLE	IF	CITATIONS
721	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. <i>Cancer</i> , 1998, 83, 409.	4.1	1
722	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. <i>Pediatric Oncology</i> , 2014, , 77-102.	0.0	1
723	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management. , 2011, , 95-105.		1
724	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018, 132, 1960-1960.	1.4	1
725	A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action. <i>Blood</i> , 2020, 136, 34-34.	1.4	1
726	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2004, 104, 2456-2456.	1.4	1
727	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3398-3398.	1.4	1
728	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. <i>Blood</i> , 2005, 106, 4447-4447.	1.4	1
729	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006, 108, 3460-3460.	1.4	1
730	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4493-4493.	1.4	1
731	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008, 112, 1011-1011.	1.4	1
732	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. <i>Blood</i> , 2010, 116, 3007-3007.	1.4	1
733	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1874-1874.	1.4	1
734	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 2705-2705.	1.4	1
735	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011, 118, 2706-2706.	1.4	1
736	The Risk of Day 100 Mortality Following Umbilical Cord Blood Transplantation Is Significantly Higher in Patients Who Do Not Achieve An ANC of 100 by Day +16 Post Transplant. <i>Blood</i> , 2011, 118, 3033-3033.	1.4	1
737	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study.. <i>Blood</i> , 2011, 118, 3968-3968.	1.4	1
738	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	1.4	1

#	ARTICLE	IF	CITATIONS
739	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. <i>Blood</i> , 2014, 124, 1138-1138.	1.4	1
740	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014, 124, 2036-2036.	1.4	1
741	Cerebral Tissue Transit Time in Patients with Sickle Cell Anemia. <i>Blood</i> , 2015, 126, 280-280.	1.4	1
742	A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism. <i>Blood</i> , 2015, 126, 3000-3000.	1.4	1
743	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015, 126, 3029-3029.	1.4	1
744	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	1.4	1
745	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2122-2122.	1.4	1
746	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2012, 19, 734-744.	1.9	1
747	TGF- β 2 Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. <i>Blood</i> , 2004, 104, 2355-2355.	1.4	1
748	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , 2006, 108, 3452-3452.	1.4	1
749	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2524-2524.	1.4	1
750	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4494-4494.	1.4	1
751	In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.. <i>Blood</i> , 2007, 110, 540-540.	1.4	1
752	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , 2007, 110, 1509-1509.	1.4	1
753	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010, 116, 1963-1963.	1.4	1
754	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 3263-3263.	1.4	1
755	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018, 132, 1981-1981.	1.4	1
756	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018, 132, 1367-1367.	1.4	1

#	ARTICLE	IF	CITATIONS
757	Melflufenâ€”A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2020, 16, 12.	0.2	1
758	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenstr�m Macroglobulinemia. <i>Blood</i> , 2021, 138, 3801-3801.	1.4	1
759	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , 2021, 138, 2733-2733.	1.4	1
760	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	1.4	1
761	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. <i>Blood</i> , 2020, 136, 27-29.	1.4	1
762	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
763	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA. , 0, , 46-63.		0
764	Proteasome Inhibition. <i>American Journal of Cancer</i> , 2004, 3, 271-279.	0.4	0
765	Proteasome inhibition as an anticancer target. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 698-698.	56.6	0
766	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. <i>Community Oncology</i> , 2006, 3, 575-582.	0.1	0
767	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Targeted Oncology</i> , 2008, 3, 19-29.	3.7	0
768	A new standard of care in newly diagnosed multiple myeloma. <i>Lancet, The</i> , 2010, 376, 2043-2044.	12.2	0
769	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
770	The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction. <i>Journal of Hematological Malignancies</i> , 2013, 3, .	0.0	0
771	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
772	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
773	Authors' reply re: Guilt, blame and litigation: can an overenthusiastic â€”safety cultureâ€” cause harm?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1622-1622.	2.5	0
774	New primary care model expands to 200 sites across England. <i>BMJ: British Medical Journal</i> , 2017, 359, j4880.	5.7	0

#	ARTICLE	IF	CITATIONS
775	Towards a better understanding of monoclonal gammopathy of renal significance. British Journal of Haematology, 2019, 186, 653-654.	2.8	0
776	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. British Journal of Haematology, 2021, 193, 213-215.	2.8	0
777	Reply to G. R. Mohyuddin et al and A. Garfall et al. Journal of Clinical Oncology, 2021, , JCO2102081.	5.3	0
778	Hepatic Venno-Occlusive Disease. , 2004, , 297-314.		0
779	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	1.4	0
780	Bortezomib Targets Multiple Myeloma Endothelial Cells.. Blood, 2004, 104, 4903-4903.	1.4	0
781	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. Blood, 2005, 106, 1551-1551.	1.4	0
782	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	1.4	0
783	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. Blood, 2005, 106, 627-627.	1.4	0
784	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. Blood, 2006, 108, 3080-3080.	1.4	0
785	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. Blood, 2006, 108, 3591-3591.	1.4	0
786	Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. Translational Medicine Series, 2007, , 169-196.	0.0	0
787	The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma. , 2008, , 291-308.		0
788	The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma. , 2008, , 239-252.		0
789	Hepatic Venno-Occlusive Disease. , 2008, , 467-493.		0
790	Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.. Blood, 2008, 112, 1690-1690.	1.4	0
791	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	1.4	0
792	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. Blood, 2009, 114, 1722-1722.	1.4	0

#	ARTICLE	IF	CITATIONS
793	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. Blood, 2009, 114, 950-950.	1.4	0
794	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. Blood, 2009, 114, 3830-3830.	1.4	0
795	PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.. Blood, 2009, 114, 612-612.	1.4	0
796	Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics. , 2011, , 29-42.		0
797	Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2010, 116, 618-618.	1.4	0
798	An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. Blood, 2010, 116, 2992-2992.	1.4	0
799	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. Blood, 2010, 116, 1838-1838.	1.4	0
800	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. Blood, 2010, 116, 451-451.	1.4	0
801	Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. Blood, 2010, 116, 4064-4064.	1.4	0
802	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. Blood, 2010, 116, 5016-5016.	1.4	0
803	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	1.4	0
804	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. Blood, 2011, 118, 815-815.	1.4	0
805	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4134-4134.	1.4	0
806	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442.	1.4	0
807	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. Blood, 2011, 118, 1377-1377.	1.4	0
808	A Novel Acanthoic Acid Analog NPI-1342 Blocks Î² Kinase-Î± and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells. Blood, 2011, 118, 1841-1841.	1.4	0
809	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	1.4	0
810	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. Blood, 2012, 120, 565-565.	1.4	0

#	ARTICLE	IF	CITATIONS
811	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0
812	Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. Blood, 2012, 120, 1847-1847.	1.4	0
813	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. Blood, 2012, 120, 1812-1812.	1.4	0
814	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. Blood, 2012, 120, 3995-3995.	1.4	0
815	Antitumor Activities Of An Oral Selective HSP90 α / β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. Blood, 2013, 122, 4429-4429.	1.4	0
816	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	1.4	0
817	Mimicking Myeloma Niche Ex Vivo. Blood, 2014, 124, 2076-2076.	1.4	0
818	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	1.4	0
819	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venous Occlusive Disease. Blood, 2014, 124, 2470-2470.	1.4	0
820	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	1.4	0
821	Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. Blood, 2015, 126, 4253-4253.	1.4	0
822	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. Blood, 2015, 126, 5322-5322.	1.4	0
823	Targeting Replicative Stress to Treat Hematological Disorders. Blood, 2015, 126, 2419-2419.	1.4	0
824	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	1.4	0
825	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 2134-2134.	1.4	0
826	Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. Blood, 2016, 128, 5689-5689.	1.4	0
827	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. Blood, 2016, 128, 5815-5815.	1.4	0
828	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. Blood, 2018, 132, 3234-3234.	1.4	0

#	ARTICLE	IF	CITATIONS
829	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation “ Results from the Tourmaline-MM1 Study. Blood, 2018, 132, 473-473.	1.4	0
830	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. Blood, 2019, 134, 318-318.	1.4	0
831	Revised international staging system allocation in the ICARIA“MM study: Practical challenges and impact on outcome. EJHaem, 0, , .	1.0	0
832	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. Blood, 2021, 138, 2732-2732.	1.4	0
833	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis. Blood, 2021, 138, 4780-4780.	1.4	0
834	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. Blood, 2021, 138, 4779-4779.	1.4	0
835	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. Blood, 2021, 138, 4969-4969.	1.4	0
836	Sinusoidal Obstruction Syndrome/Hepatic Venous Occlusive Disease. , 2022, , 143-163.		0
837	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. Blood, 2020, 136, 31-31.	1.4	0
838	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. Blood, 2020, 136, 20-22.	1.4	0
839	Variation in the Treatment of Multiple Myeloma in the Real World. Blood, 2020, 136, 43-44.	1.4	0
840	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	0
841	Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML. Journal of Clinical Oncology, 0, , .	5.3	0
842	Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE“MM2 trial. EJHaem, 0, , .	1.0	0
843	Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the <sc>OCEAN study</sc>. European Journal of Haematology, 2024, 112, 402-411.	2.3	0
844	Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the <sc>GRIFFIN</sc> study. British Journal of Haematology, 2024, 204, 2227-2232.	2.8	0
845	Health“related quality of life in transplant“eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient“reported outcomes from <sc>GRIFFIN</sc>. American Journal of Hematology, 2024, 99, 1257-1268.	4.3	0
846	Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow“up subgroup analysis of the <sc>BOSTON</sc> trial. European Journal of Haematology, 2024, 113, 242-252.	2.3	0

#	ARTICLE	IF	CITATIONS
847	Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. <i>Blood Cancer Journal</i> , 2024, 14, .	6.4	0
848	An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 0, , .	2.3	0
849	Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence. <i>British Journal of Haematology</i> , 0, , .	2.8	0
850	Targeting ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. <i>Expert Review of Hematology</i> , 0, , .	2.2	0
851	Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. <i>Blood Cancer Journal</i> , 2024, 14, .	6.4	0